menu
    • menu
    [{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2020","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Evergreen Theragnostics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Agreement","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Cellectar"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2024","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Rosalind Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2024","type":"Private Placement","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Rosalind Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Rosalind Advisors"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Inapplicable","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Meaningful Insights-BioTech Analytics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2024","type":"Partnership","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ Meaningful Insights-BioTech Analytics","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ Meaningful Insights-BioTech Analytics"},{"orgOrder":0,"company":"Cellectar","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2021","type":"Funding","leadProduct":"131-I Iopofosine","moa":"DNA cross-linking","graph1":"Oncology","graph2":"Phase II","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cellectar \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"8","companyTruncated":"Cellectar \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"Cellectar","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CLR131","moa":"Tumor cell lysis","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Cellectar \/ National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Cellectar \/ National Cancer Institute"},{"orgOrder":0,"company":"Cellectar","sponsor":"IntoCell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Undisclosed","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"1","companyTruncated":"Cellectar \/ Cellectar"},{"orgOrder":0,"company":"Cellectar","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Inapplicable"},{"orgOrder":0,"company":"Cellectar","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Public Offering","leadProduct":"CLR 125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Cellectar","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Public Offering","leadProduct":"CLR 125","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Cellectar","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"5","companyTruncated":"Cellectar \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Cellectar","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"CLR 121225","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Cellectar","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectar \/ Cellectar","highestDevelopmentStatusID":"4","companyTruncated":"Cellectar \/ Cellectar"}]

    Find Clinical Drug Pipeline Developments & Deals by Cellectar

    Menu

    Cellectar

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLR 125

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Ladenburg Thalmann & Co

                            Deal Size : $6.9 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering

                            Details : The Company currently intends to use the net proceeds to initiate a Phase 1b of CLR 121125 (CLR 125) in triple-negative breast cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 02, 2025

                            Lead Product(s) : CLR 125

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Ladenburg Thalmann & Co

                            Deal Size : $6.9 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLR 125

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Ladenburg Thalmann & Co

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

                            Details : The Company currently intends to use the net proceeds to initiate a Phase 1b of CLR 121125 (CLR 125) in triple-negative breast cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 01, 2025

                            Lead Product(s) : CLR 125

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Ladenburg Thalmann & Co

                            Deal Size : $6.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLR 121225

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            NorthStar Supplies Actinium-225 to Cellectar Biosciences for Therapeutic Use

                            Details : NorthStar will provide non-carrier added actinium-225 (n.c.a Ac-225) to Cellectar for use in CLR 121225, an actinium-labeled PLE, expected to enter a Phase 1 study in pancreatic cancer.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 21, 2024

                            Lead Product(s) : CLR 121225

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Meaningful Insights-BioTech Analytics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Cellectar Partners with MiBA to Advance Waldenstrom's Macroglobulinemia Treatment

                            Details : The partnership aims to advance the treatment of Waldenstrom's macroglobulinemia with Cellectar’s iopofosine I 131, a novel phospholipid radiotherapeutic conjugate.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Undisclosed

                            November 01, 2024

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Meaningful Insights-BioTech Analytics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellectar Announces Positive Data Achieving Primary Endpoint in Waldenstrom’s Study

                            Details : CLR 131 (Iopofosine I 131) is a potential first-in-class, targeted radiotherapy candidate, which is under phase 2 clinical development for relapsed/refractory Waldenstrom’s macroglobulinemia.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            August 01, 2024

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Rosalind Advisors

                            Deal Size : $44.1 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Cellectar Fully Exercises Tranche A Warrants, Raising $44.1 Million

                            Details : Net proceeds will fund CLR 131 (iopofosine I-131), designed for targeted iodine-131 delivery to cancer cells, being evaluated for Waldenstrom Macroglobulinemia and other cancers.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Undisclosed

                            January 25, 2024

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Rosalind Advisors

                            Deal Size : $44.1 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLR 121225

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellectar Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors

                            Details : CLR 121225 (225Ac-CLR-121225) is an actinium-labeled phospholipid ether. It is a novel α-emitting phospholipid radiotherapeutic conjugate. It is being evaluated for refractory pancreatic cancer.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 16, 2024

                            Lead Product(s) : CLR 121225

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CLR131

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 09, 2022

                            Lead Product(s) : CLR131

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cellectar Announces Publication of Data from Its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-...

                            Details : I-131-CLR1404 (Iopofosine I 131) is a small-molecule Phospholipid Drug Conjugate™ designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Inapplicable

                            September 13, 2022

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed

                            Cellectar

                            U.S.A arrow
                            Peptide Process CMC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldens...

                            Details : The grant will be used to support and accelerate the ongoing pivotal study of iopofosine I-131 (CLR 131) in Waldenstrom’s macroglobulinemia (WM) patients who have received at least two prior lines of therapy.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compounds

                            Upfront Cash : Undisclosed

                            August 18, 2021

                            Lead Product(s) : 131-I Iopofosine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : The Division of Cancer Treatment and Diagnosis

                            Deal Size : $2.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth